Ultragenyx Analyst Day Presentation

Revenue ($M) 2024 revenue growth expected to be ~20% driven by Crysvita in the U.S. and Latin America Annual Revenue Growth¹ 500 400 300 200 100 $28M 2018a $103M 2019a $182M 2020a $266M 2021a $356M 2022a 1 Excludes Bayer and Daiichi collaboration revenue and includes preliminary estimates for 2023 and 2024 Confidential and Proprietary $434M Product $500-530M 2023 Actual 2024 Guidance Crysvita¹ $328M $375-400M 14% to 22% growth Dojolvi $71M $75-80M 6% to 13% growth 2023a 2024e $500-530M Total Revenue² $434M 15% to 22% growth 1 Total Crysvita revenue, including North America, Latin America, and Europe 2 Total Revenue includes Crysvita, Dojolvi, Mepsevii, and Evkeeza ultragenyx

View entire presentation